Alice founders, Elizabeth Gore (left) and Carolyn Rodz, will talk more about the partnership at Bumble's SXSW event, which the duo attended last year. Getty Images

Rather than just imagining a world where investments made are representative of the diverse population, these two tech companies with Texas roots are teaming up to do something about it.

Austin-based Bumble, a social network with over 50 million users, has reached a deal with Alice, an artificial intelligence-powered platform for entrepreneurs founded by Houstonian Carolyn Rodz and Californian Elizabeth Gore, to use the platform for Bumble's next round of funding.

Additionally — but actually separate from the partnership — Bumble Fund, an early stage corporate investing vehicle focused on businesses founded and led by underrepresented women founders, has invested in Alice in its most recent round of funding.

"We are looking to invest in entrepreneurs whose company purpose solves a problem that disproportionately affects women," says Sarah Jones Simmer, COO at Bumble, in a release. "While we can't fund every promising business and entrepreneur, we strongly believe these companies and founders deserve access to grow, evolve, and thrive. Through community, access to experts, how-to guides, and more, Bumble and Alice are committed to helping women founders find the support and resources they need on their path to success."

The next cohort of fund recipients of the Bumble Fund will be applying through Alice's website, which provides education, support, mentorship and guidance to burgeoning startup founders. Even if applicants don't get funding from Bumble, they leave with a network of resources.

The partnership with Alice will allow Bumble to better connect the dots of its fund recipients using data and AI, and even help to eliminate any bias when it comes to selecting the recipients. The fund is open to all United States entrepreneurs who identify as women. It launched in summer of last year and cuts checks ranging from $5,000 to $250,000, with an average of $25,000.

"For the last several years, only 2 percent of venture capital went to women founders. At Alice and Bumble, we see that as a 98 percent opportunity," says Rodz in the release. "The Bumble Fund, powered by Alice, is that opportunity in action; together, we're going to rewrite the rules of venture capital to be more accessible, more transparent and more supportive for women founders."

Here are all four of Bumble Fund's second round of recipients, according to the release.

  • Alice - founded by Carolyn Rodz and Elizabeth Gore: an AI-powered technology helping entrepreneurs find the right path to start and grow their companies.
  • Gixo - founded by Selina Tobaccowala: a fitness company founded to improve global health and activity rates by democratizing access to live workouts with professional trainers.
  • Translator - founded by Natalie Egan: the world's most advanced diversity & inclusion training system for corporations, schools and nonprofits.
  • Promise - founded by Phaedra Ellis-Lamkins: a technology company that creates cost-effective, equitable, and humane alternatives to incarceration with a mission to get people out of jail and provide ongoing support to help them stay out.

Bumble's first round of investments were in Beautycon, Cleo Capital, Female Founders Fund, Mahmee, and Sofia Los Angeles, a winner of the inaugural Bumble Bizz Pitch Competition.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.